iDNA Laboratories

What iDNA Laboratories does

iDNA Laboratories is a Greek precision medicine genetics company founded in 2021 and headquartered in Kifisia, Athens. The company develops and markets three CE-IVD-marked in vitro diagnostic genetic tests: iDNA PGx CNS (pharmacogenetic analysis of 24 polymorphisms guiding CNS medication selection and dosing), iDNA Cardio Health (polygenic risk scoring for six cardiovascular diseases), and iDNA NutriGenetix (personalized nutrigenetic-based diet planning). Genotyping is performed on QuantStudio 12K Flex Real-Time PCR systems using Applied Biosystems OpenArray and Microarray technology, with results interpreted through a proprietary bioinformatics platform that continuously updates with the latest scientific literature and is delivered to patients and physicians via the myEMR digital portal. The laboratory holds ISO 13485:2016, ISO 9001:2015, and ISO 27001:2013 certifications and has conducted the largest pharmacogenetic study in the Greek population (n=3,011).

The business model is one-time in vitro diagnostic test sales priced at €140 publicly for iDNA PGx CNS (with approximately 50% EOPYY reimbursement available for resistant depression), distributed exclusively through prescribing physicians (psychiatrists, cardiologists, neurologists, endocrinologists, GPs), a nationwide network of more than 100 partner diagnostic centers, and Greek pharmacies. Over 4,000 patients have used the PGx CNS test cumulatively. The go-to-market relies on scientific credibility through peer-reviewed publications, medical-conference presence (including satellite symposiums with VIANEX at major Greek psychiatry and psychopharmacology congresses), physician education via a Medical Science Liaison team, and content partnerships with Greek media such as CNN Greece. In March 2024, VIANEX Group, a Greek pharmaceutical and healthcare company, made a strategic investment in iDNA Laboratories and its affiliate iDNA Genomics to support expansion.

The company operates with a small team of approximately seven professionals, including certified Clinical Laboratory Geneticists (EBMG/ErCLG), a Data Scientist, a Bioinformatician, a Nutrition and Genetics Specialist, and a Lab Manager, supported by academic advisors from the University of Athens Faculty of Pharmacy and Medical School. There are no disclosed institutional investors beyond VIANEX, no public listing, and the company remains privately held. All operations and revenue are contained within Greece, with no international geographic expansion disclosed to date.

Name

iDNA Laboratories

Legal name

iDNA Laboratories

Website

https://idnalaboratories.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

iDNA Laboratories is a Greek precision medicine genetics company that develops CE-IVD-marked pharmacogenetic, cardiovascular PRS, and nutrigenetic tests, sold through physicians, 100+ partner diagnostic centers, and pharmacies in Greece.

Ownership category

akta.pro rank

Product category

Genetic Diagnostic Testing

NAICS

Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industries

Reference & Esoteric Testing Laboratories (HLAFAMAJ), Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays (HLAAALAN), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)

Keywords

• Pharmacogenetic testing
• Cardiovascular risk assessment
• Nutrigenetic analysis
• In vitro diagnostics
• Precision medicine

Headquarters

HQ city

Kifisia (Athens)

HQ country

Greece

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. iDNA PGx CNS — Pharmacogenetic Test: One-time in vitro diagnostic test sold through healthcare professionals (prescribing physicians) and pharmacies. Price is publicly listed at €140 per test. The test analyzes 24 gene polymorphisms to guide CNS medication selection. Report delivery within 15 working days. For resistant depression indication, the test is partially reimbursed by EOPYY (Greek national health insurer), with approximately 50% reimbursement.
2. iDNA Cardio Health — Cardiovascular PRS Test: One-time in vitro diagnostic test for genetic predisposition to 6 cardiovascular diseases using Polygenic Risk Score and Adjusted PRS. Results delivered within 20 working days. Sold through healthcare professionals.
3. iDNA NutriGenetix — Nutrigenetic Test: One-time in vitro diagnostic test combining genetic analysis with phenotypic and lifestyle data to generate personalized diet plans. Sold through healthcare professionals. Report includes individualized nutritional plan with alternative meal suggestions.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

iDNA Laboratories designs, develops, and offers CE-marked in vitro diagnostic genetic tests (iDNA PGx CNS, iDNA Cardio Health, and iDNA NutriGenetix) performed from oral swab samples in its certified laboratory. The tests deliver personalized pharmacogenetic, cardiovascular polygenic risk, and nutrigenetic reports exclusively through treating physicians, partner diagnostic centers, and pharmacies across Greece, supported by the myEMR digital results platform.

Product overview

iDNA Laboratories offers a portfolio of three CE-marked in vitro diagnostic genetic testing products, all performed once-in-a-lifetime from oral swab samples. iDNA PGx CNS provides pharmacogenetic analysis for CNS medications to guide psychiatric and neurological treatment. iDNA Cardio Health assesses cardiovascular disease predisposition using polygenic risk scoring. iDNA NutriGenetix delivers personalized nutrition and weight management recommendations. All products are supported by the myEMR platform for result delivery and ongoing patient-provider communication.

Differentiator

Problem solved

Functional benefit

Brands

• iDNA PGx CNS: Pharmacogenetic analysis test for Central Nervous System drugs, providing guidance on drug selection and dosage to achieve optimal response and minimize side effects.
• iDNA Cardio Health
• iDNA NutriGenetix

Products and services

• iDNA PGx CNS In vitro pharmacogenetic diagnostic test that analyzes 24 genetic polymorphisms across drug-metabolizing genes to guide personalized CNS medication selection, dosage optimization, and prediction of drug response and adverse effects for antidepressants, antipsychotics, and antiepileptics. Provided exclusively through treating physicians and pharmacies in Greece; results delivered within 15 working days.
• iDNA Cardio Health In vitro diagnostic test using Polygenic Risk Score (PRS) and Adjusted PRS to estimate genetic predisposition for 6 cardiovascular diseases including coronary artery disease, cardiomyopathies, heart failure, atrial fibrillation, and ischemic stroke. Sold through healthcare professionals with results delivered within 20 working days.
• iDNA NutriGenetix In vitro diagnostic test combining genetic analysis with phenotypic data and lifestyle questionnaire to provide personalized nutrition plans, individualized energy and macronutrient requirements, and tailored dietary advice for weight management and metabolic health optimization. Sold through healthcare professionals.
• myEMR Digital Platform Patient and healthcare provider portal for managing genetic test results, accessing personalized reports, registering test kits, and receiving updated analyses when new scientific data becomes available. Available via web portal and iOS and Android mobile apps.

Quantifiable outcome

• 96% of patients responded positively to personalized pharmacogenetic-guided treatment
• +7 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Partnerships

15 partnerships are on record, tiered minor and major.

• University of ThessalyminorOthersResearch partnership for a survey on dietitian perspectives on nutrigenetics in Greece. The study was conducted in collaboration with the University of Thessaly and the National Research Foundation (EIE/NHRF). Results showed 81% of Greek dietitians believe nutrigenetic applications could improve their practice, and 82% would be interested in genetics training.
• National Research Foundation (EIE/NHRF)minorOthersCollaborated with University of Thessaly and iDNA Laboratories on a survey study regarding dietitian perspectives on nutrigenetics in Greece.
• Lifecheck Diagnostic CentersmajorChannel Partner/ Reseller/ DistributorNationwide network of over 20 Lifecheck diagnostic centers across Greece (Psychiko, Ilioupoli, Melissia, V.Sofias, Lagonisi, Koridallos, Kallithea, Faliro, Neos Kosmos, Koropi, Anavyssos, Drapetsona, Kaisariani, Kalyvia, Kalamaki, Nea Smyrni, Haidari, Alimos, Holargos, etc.) serving as sample collection points for iDNA genetic tests.
• Alpha Prolipsis Diagnostic CentersmajorChannel Partner/ Reseller/ DistributorThree Alpha Prolipsis diagnostic centers in Psychiko, Dafni, and Glyfada serving as partner sample collection locations for iDNA genetic tests across Greece.
• MYLAB Diagnostic CentersmajorChannel Partner/ Reseller/ DistributorFive MYLAB diagnostic centers in Stavroupoli, Kalochori, Toumpa, Kentro, and Ntepo in Thessaloniki serving as partner sample collection locations for iDNA genetic tests.
• Minoan LabsmajorChannel Partner/ Reseller/ DistributorThree Minoan Labs locations in Heraklion, Crete (PAGNI, Mastabas, Kentro) serving as partner sample collection centers for iDNA genetic tests.
• Bioereuna Diagnostic LaboratoriesmajorChannel Partner/ Reseller/ DistributorBioereyna Diagnostic Laboratories (IMEPE) with central laboratory and branch in Chania, Crete serving as partner sample collection centers for iDNA genetic tests.
• DIMITRIOS Diagnostic Centers (Evros)majorChannel Partner/ Reseller/ DistributorFour DIMITRIOS diagnostic centers in Xanthi, Alexandroupoli, Orestiada, and Didymoteicho serving as partner sample collection locations for iDNA genetic tests in the Evros region.
• Sakarellos Diagnostic CentersmajorChannel Partner/ Reseller/ DistributorTwo Sakarellos diagnostic centers in Nea Erythraia and Anoixi (Attica) serving as partner sample collection locations for iDNA genetic tests.
• Evoanalisi Diagnostic LaboratoriesmajorChannel Partner/ Reseller/ DistributorFour Evoanalisi diagnostic laboratories in Didymoteicho, Orestiada, Kardia, and Samothraki serving as partner sample collection locations for iDNA genetic tests in the Evros region and Northern Greece.
• Asklepieio Diagnostic CentersmajorChannel Partner/ Reseller/ DistributorThree Asklepieio diagnostic centers in Edessa, Giannitsa, and Veria serving as partner sample collection locations for iDNA genetic tests in Central Macedonia.
• Biomedica Diagnostic Center of KastoriaminorChannel Partner/ Reseller/ DistributorBiomedica diagnostic center in Kastoria serving as a partner sample collection location for iDNA genetic tests.
• Biomorfi Diagnostic CentersminorChannel Partner/ Reseller/ DistributorThree Biomorfi diagnostic centers in Ilion and Petroupoli serving as partner sample collection locations for iDNA genetic tests.
• Falireas Medical CentersminorChannel Partner/ Reseller/ DistributorFour Falireas Medical centers in Kalamata, Meligalas, Pylos, and Stoupa serving as partner sample collection locations for iDNA genetic tests in the Peloponnese region.
• Eurodiagnosis Diagnostic CentersminorChannel Partner/ Reseller/ DistributorThree Eurodiagnosis diagnostic centers in Thermi (Metamorphosis), Adriani (Kalamaria), and Pavlou Mela (Evosmos) in Thessaloniki area serving as partner sample collection locations.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• EasyDNA: International genetic testing provider offering health, PGx, nutrition, and wellness DNA tests through partner networks. Comparable in test-menu breadth and direct-to-physician/consumer channels, though smaller and less differentiated than iDNA's clinical-grade PGx CNS offering.
• Mapmygenome: India-based predictive genomics company offering pharmacogenomic, polygenic risk, and nutrigenetic tests through clinicians. Comparable as an emerging regional player with a similar physician-channel PGx and preventive-genetics test portfolio, though operating in a different geography.

Broad incumbents

• Genomics England: UK-government-backed genomic medicine initiative operating large-scale population sequencing and clinical genetics infrastructure. Comparable as an established reference-genomics organization in clinical genetics, though operating at a national rather than commercial scale.
• MyHeritage DNA: Israel-headquartered consumer genetics service offering health and ancestry reports across Europe and globally. Comparable as a broad-incumbent genetics brand in the same consumer/clinical-adjacent DNA testing category, though focused primarily on ancestry.
• 23andMe: US-headquartered global consumer genetics giant offering health predisposition, pharmacogenomic, and trait reports. Comparable in product categories (PGx, polygenic risk, wellness genetics) but operates at vastly greater scale via direct-to-consumer rather than physician-channel distribution.

Direct peers

• DNAlysis Biotechnology: South Africa-based specialist in pharmacogenomic testing (PainPGx, MindPGx, Mental Health DNA insights). Highly comparable product focus (PGx for psychiatric medications) with physician-channel distribution and proprietary reporting — the closest functional analog to iDNA PGx CNS.
• GenePlanet: Slovenia-headquartered preventive genetics company offering pharmacogenomic, polygenic-risk, nutrigenetic, and lifestyle DNA tests across Europe. Comparable because it sells directly through healthcare professionals and partner networks with a similar multi-test portfolio including PGx and nutrition.
• Centogene: Germany-headquartered molecular diagnostics company offering rare-disease genetic testing, PGx, and clinical genomics across Europe and the Middle East. Comparable as a CE-IVD-certified clinical genomics lab selling physician-prescribed genetic tests through similar partner-center and hospital channels.
• Eurofins Genoma Group: Italy-based molecular genetics laboratory offering PGx, prenatal, oncology, and rare-disease genetic testing. Comparable as a Southern European clinical genetics lab with a similar multi-test menu, CE-IVD-marked assays, and physician-driven distribution model.
• Medicover Genetics: Sweden-based clinical genetics laboratory offering pharmacogenomics, hereditary cancer, and reproductive genetics across Europe. Comparable CE-IVD-certified lab with physician-prescribed testing, multi-test portfolio, and population-level clinical evidence generation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/idna-laboratories

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about iDNA Laboratories